Dissecting Cellulitis of the Scalp Successfully Treated with a Combination of Ixekizumab and Tofacitinib

A 28-year-old Chinese man with severe dissecting cellulitis of the scalp (DCS), a rare form of primary cicatricial alopecia, was successfully treated with a combination of ixekizumab, an IL-17 inhibitor, and tofacitinib, a Janus kinase inhibitor. This case marks the first reported instance of using this combination therapy for DCS, resulting in significant regression of scalp abscesses and hair regrowth after 3 months, with continued improvement over 10 months. The treatment was well-tolerated without serious adverse events, suggesting that this combination could be a promising strategy for managing severe DCS, although larger trials are needed to confirm its efficacy and safety.